Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech to Build $100 Million R&D Center in Wuhan

publication date: Aug 11, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech will spend $100 million to build a new R&D facility in the central China city of Wuhan. The company will construct a 40,000 sq meter CRO facility in the Wuhan National Biological Industry Base (Optics Valley of BioLake). Wuhan sources told ChinaBio® that a cooperative agreement between WuXi and the Wuhan Biological Base was signed on August 9. More details....

Stock Symbol: (NYSE: WX)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners